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Antibody-mediated rejection (AMR) (humoral rejection) of cardiac allografts remains diﬃcult to diagnose and treat. Interest
in AMR of cardiac allografts has increased over the last decade as it has become apparent that untreated humoral rejection
threatens graft and patient survival. An international and multidisciplinary consensus group has formulated guidelines for the
diagnosis and treatment of AMR and established that identiﬁcation of circulating or donor-speciﬁc antibodies is not required
and that asymptomatic AMR, that is, biopsy-proven AMR without cardiac dysfunction is a real entity with worsened prognosis.
Strict criteria for the diagnosis of cardiac AMR have not been ﬁrmly established, although the diagnosis relies heavily on tissue
pathological ﬁndings. Therapy remains largely empirical. We review an unfortunate experience with one of our patients and
summarize recommended criteria for the diagnosis of AMR and potential treatment schemes with a focus on current limitations
and the need for future research and innovation.
1.Background
Humoral rejection is now clearly established to be a major
threat to graft and patient survival after cardiac transplan-
tation.Unfortunately,ourdiagnosisandtreatmentofcardiac
allograft dysfunction has revolved mainly around under-
standing the cellular response and our insight into the recog-
nition of antibody-mediated rejection (AMR) and conse-
quently our ability to treat AMR has lagged. Humoral rejec-
tion of cardiac allografts diﬀers from cellular rejection by
targeting endothelial cells leading to the production of a
capillary vasculopathy and by the inﬁltration of neutrophils
and macrophages rather than T cells. Pathological diagnosis
involves providing evidence of endothelial injury and anti-
body and complement deposition [1]. Thus, the diagnosis is
heavily dependent on tissue biopsy conﬁrmation. We present
a recent case of ours with fatal AMR that was diagnosed
postmortem and not detected by surveillance or clinically
directed biopsies. Furthermore, our patient developed no
detectable circulating or donor-speciﬁc antibodies. Diagnos-
tic and treatment recommendations for AMR are reviewed.
We outline the diﬃculties and complexity of this devastating
cause of morbidity and mortality in cardiac transplantation.
2. Patient Case
A 24-year-old woman with a complex medical history that
included idiopathic thrombocytopenic purpura requiring
splenectomy and recent postpartum acute respiratory dis-
tress syndrome requiring ﬁve days of ventilatory support was
transferred to our facility from a local hospital at three
months postpartum in severe cardiogenic shock. She was
found to have nonischemic cardiomyopathy which required
emergent biventricular paracorporeal ventricular assist devi-
ces (Thoratec CentriMag, Thoratec Corp., Pleasanton, Ca-
lif, USA). After stabilization and recovery, she was listed as2 Journal of Transplantation
aUNOSstatus1A(ABO,A−)forhearttransplantationwith-
out detectable panel reactive antibodies (PRAs). Approxi-
mately two months subsequent to VAD placement, she un-
derwentorthotopichearttransplantationwithanHLA-com-
patible cadaveric heart (ABO, A+). She had a persistent post-
operative coagulopathy requiring transfusion of multiple
packed red blood cells, fresh frozen plasma, and platelets and
eventual return to the operating room for washout and re-
exploration within 24 hours of transplantation. Her retro-
spective cross-match was negative, and subsequent tests for
donor-speciﬁc antibodies and anti-HLA circulating antibod-
ies were negative using the Luminex solid-phase assays. She
was tested for circulating antibodies multiple times through-
out her care and during her ﬁnal admission.
Her transplant course was complicated by multiple com-
plications but most notably for recurrent severe infections
mandating reduction in her immunosuppressive regimen.
Her infections included severe genital wart outbreaks of the
perineum requiring nine separate intraoperative fulgura-
tions, as well as debridement of recurring perivulvar and
peri-anal abscesses and ﬁstula, CMV viremia and recurrent
C. diﬃcile diarrhea requiring oral vancomycin. Her medical
complications included renal insuﬃciency, severe bifrontal
chronic headaches requiring change in immunosuppression
from tacrolimus to cyclosporine, recurrent supraventricular
tachyarrhythmias with ablation therapy, antiphospholipid
antibody syndrome requiring chronic warfarin anticoagula-
tion and a thrombotic cerebrovascular accident without re-
sidual neurologic sequelae.
The patient’s immunosuppressive regimen included tac-
rolimus, mycophenolate mofetil (MMF), and corticoster-
oids during the initial transplant period. Her steroids were
weanedduringtheﬁrstthreemonthsanddiscontinuedcom-
pletely in the maintenance period because of the recurrent
infections described above and her preoperative history of
splenectomy. By fourteen months postoperatively, she was
converted to cyclosporine. Her headaches resolved after the
change in calcineurin inhibitor. For the last twelve months of
her life, she was treated with two drug therapy, cyclosporin
andMMF.Hercyclosporindosewasintermittentlydecreased
when she presented with clinical infections. Her MMF dose
was decreased during infections or episodes of neutropenia
from 1000mg twice a day to 500mg twice a day but main-
tained at 1000mg twice a day during her ﬁnal 12 months.
In her ﬁnal week, her cyclosporine was reduced from 150mg
twice a day to 75mg twice a day. Her trough cyclosporine
levels were maintained at around 200ng/mL in her ﬁnal
months but during periods of infection were allowed to drop
below 100ng/mL.
Despite the required changes in her immunosuppressive
regimen, the patient had only one documented episode of
mild cellular rejection diagnosed at biopsy in the ﬁrst per-
ioperative month. She gradually developed evidence for mild
diastolic dysfunction over the ﬁrst two years following trans-
plantation. Based on left and right heart catheterization re-
sults and echocardiographic and biopsy results, there was
concern that she was developing mild constrictive or restric-
tive physiology. Her ejection fraction gradually decreased
from 70% in the ﬁrst few months after transplantation to
50% at 29 months after-transplant. She showed no evidence
of signiﬁcant mitral or tricuspid regurgitation. Heart biop-
sies taken throughout her course and during the months
that she developed cardiac dysfunction showed no evidence
for cellular or humoral rejection. The evaluations included
stainingforC4d(complementproduct)andCD68(amacro-
phage speciﬁc marker). She underwent two heart biopsies in
herlastninemonthswiththelastbeing4monthspriortoher
death. Again, both of these biopsies were negative for cellular
andhumoralrejectioninthesettingofworseningventricular
function. Left heart catheterization showed no evidence of
coronary vasculopathy.
At approximately 29 months after transplantation, the
patient was admitted for diarrhea, dehydration, emesis, and
acute renal insuﬃciency. She responded well to rehydration;
however,sheexperiencedanepisodeofhypoxemialeadingto
complete heart block from which she was easily resuscitated
but required intubation. A urine screen was positive for both
temazepam and alprazolam, which the patient had been pre-
scribed as an outpatient and the cause of her arrest was at-
tributed to hypoxemia secondary to hypoventilation and se-
dation. She was subsequently noted to have right upper and
left lower extremity swelling, and ultrasound revealed super-
ﬁcial venous thrombosis, despite continued Coumadin anti-
coagulation. A chest scan to rule out pulmonary embolism
was performed and was negative. She became febrile and was
placed on broad-spectrum antibiotics. On the day of her
death, she developed recurrent third-degree heart block and
ventricular tachycardia. Despite aggressive resuscitation ef-
forts, she died that evening. An autopsy was performed, and
although the initial gross evaluation failed to show the cause
of her graft failure, histologic and pathologic myocardial sec-
tions eventually revealed severe but patchy cellular and anti-
body-mediated rejection. (Figures 1, 2(a), 2(b),a n d3 show
thepathologicﬁndingsofantibody-mediatedrejectioninthe
case described here.)
3. Review and Discussion
3.1. Overview. The case presented here, although truly un-
fortunate in its outcome and unusual in its presentation be-
cause of the insidious recurrent infections, illustrates the
complexdiﬃcultiesencounteredinthemanagementofheart
transplant recipients. First, we have no adequate measure of
the degree of immunosuppression. This patient’s history of
recurrent and life-threatening infections obliged us to alter
our immune therapy. However, we did so without the exis-
tence of an adequate measure of the “immune state.” While
we did measure drug levels and peripheral blood cell counts,
we did not have a set of parameters or reliable markers which
could tell us in a prognostic and diagnostic manner this pa-
tient’s risk of rejection or infection as we altered her immune
therapy. This limitation exists in the management of all car-
diac recipients. Ultimately our patient developed fatal cellu-
lar and humoral rejection. Second, this lack of a noninvasive
predictiveclinicalmeasureforcesclinicianstotakeanexpect-
ant approach, that is, an approach referred to as “height-
ened rejection surveillance.” This approach, which involves
increasingthenumberandfrequencyofbiopsiesisessentiallyJournal of Transplantation 3
Figure 1: Antibody-mediated rejection characterized by endothe-
lial cell swelling and numerous macrophages ﬁlling vascular spaces.
a “wait and see” approach. Thus, as clinicians, we are obli-
gatedtomanageimmunosuppressionbyreactingtothemost
recent adverse event. Third, endomyocardial biopsies “the
gold standard” for detecting rejection, can fail to detect both
cellular and humoral rejection. This is a direct result of the
fact that these pathophysiologic rejection processes are not
homogenous and, thus, the heart biopsy in addition to its
direct risk of injury to the heart and the patient is inherently
limited by the fact that it is a random sample. Interobserver
variability has also been shown to be a limitation of the car-
diac biopsy [2]. The case presented here illustrates clearly the
clinical consequences of the heterogeneous, patchy nature of
both cellularand antibody-mediated rejection. Thus, asigni-
ﬁcant risk of a false-negative biopsy result exists. Fourth, the
clinician on suspicion alone is often forced to treat suspected
rejection events empirically with direct pathologic conﬁrma-
tion lacking. We were reluctant to do this for this patient
without tissue conﬁrmation because of the incessant and
recurrent life-threatening infections in her posttransplant
course.Equallycomplicatingistheambiguityofdeﬁningand
treating antibody-mediated rejection, a diagnosis dependent
on biopsy proof with or without detectable circulating or
donor-speciﬁc HLAantibodies. Inthis patient’s case,thelack
of pathologic conﬁrmation and the lack of detectable circu-
lating antibodies made it diﬃcult to treat her empirically for
AMR.
3.2. Gene-Expression Proﬁling. The goal of developing a
prognostic and diagnostic test that is a measure of the pa-
tient’s “immune state,” that is minimally invasive and that
could ultimately be used to diminish the need for endomy-
ocardialbiopsieshasbeenapproachedaggressivelybystudies
supported by XDx, Inc. (Expression Diagnostics) in two ma-
jor clinical studies. The ﬁrst study, entitled CARGO (Cardiac
Allograft Rejection and Gene Observation), was published
in 2006 and led to the development of a proprietary gene
expression test called the Allomap [2, 3]. The hypothesis
as stated by the company in performing the CARGO study
was that a gene-expression pattern in the peripheral blood
mononuclear cells could discriminate between patients with
(a)
(b)
Figure 2: (a) Antibody-mediated rejection, high power. Longitudi-
nal section of capillary with mild endothelial cell swelling and ma-
crophages accumulating in lumen. (b) Immunoperoxidase staining
with CD68 highlights the macrophages.
no rejection and those with moderate or severe cellularrejec-
tion. By identifying low-risk patients for rejection, a subset
of patients could be monitored without the need for invasive
biopsies. They assumed that gene expression proﬁling in the
peripheral blood would predict rejection at the organ level.
The CARGO study identiﬁed 11 classiﬁer genes involved in
important immune activation pathways including T-cell ac-
tivation, T-cell migration and macrophage activation, hem-
atopoiesis, and steroid responsiveness. The initial ﬁndings of
the CARGO study (Deng et al. [3]) were corroborated by the
ﬁrst clinical experience published by Starling et al. [4]. The
Allomap was developed and consists of the 11 classiﬁer genes
and 9 control genes. The assay has a sensitivity of 84.6%
at identifying the low-risk patient and a negative predictive
value of 99.6%. The CARGO investigators note, however,
thatthehistoricallylabeled“goldstandard,”theendomyocar-
dial biopsy, suﬀers from signiﬁcant interobserver variability
and is, thus, an imperfect tool to use for gene discovery. Pre-
viousstudiesha v ec onﬁrmedthediﬃcultyofusingtheendo-
myocardial biopsy as a gold standard and documented inter-
observer variability [2].
Allomap is now available on the market but has been
received with signiﬁcant skepticism and the lack of enough4 Journal of Transplantation
Figure 3: Antibody-mediated rejection, high power. C4d decorates
endothelial cells in this immunoperoxidase-stained slide.
clinical validation has made it diﬃcult to get insurance com-
panies to pay for it. To address this, a multidisciplinary and
multiinstitutional study group was formed that included 13
US cardiac transplant centers [5]. The study group set up a
trial called Invasive Monitoring Attenuation through Gene
Expression (IMAGE) whose goal was to validate the use of
gene expression proﬁling for rejection surveillance. The re-
sults were published last year, and the investigators conclud-
ed that there was noninferiority of gene expression proﬁling
with endomyocardial biopsy in rejection surveillance after
cardiac transplant. The study was met with criticism for sev-
eral reasons among which was the fact that most patients
wereenrolledmorethanayearaftertransplantationatatime
when cardiac biopsy is of unproven beneﬁt [6]. The highest
risk of acute cellular rejection for cardiac allografts occurs in
theﬁrstsixmonthswithagraduallytaperingriskthroughout
the ﬁrst year. Furthermore, both the gene expression pro-
ﬁling and the cardiac biopsies were poor at predicting the
endpoints of the study. While somewhat disappointing at
predicting rejection, the gene-expression proﬁling did prove
non-inferiority to an imperfect “gold-standard” and the ap-
proach is highly attractive because of the potential for both
prognostic and diagnostic information and the minimal risk
peripheral blood gene expression proﬁling poses.
3.3. Diagnosing Humoral Rejection. Antibody-mediated re-
jection still poses unanswered and complex questions. The
roleofantibody-mediatedrejectioninacuteandchroniccar-
diac allograft dysfunction is now ﬁrmly established [7–9].
However, the topic has been steeped in controversy in heart
transplantationstemmingfromaninabilityformanyyearsto
come to a consensus on the clinical and pathologic diagnosis
and on the appropriate treatment [10–12]. In part, the dif-
ﬁculty in deﬁning this process arises from the still emerging
understanding of the cellular and molecular mechanisms in-
volved. The lack of a consensus on these issues has made it
diﬃcult to assess the true incidence of cardiac humoral re-
jection. Over the last ﬁve years, the International Society of
Heart and Lung Transplantation has published two consen-
sus papers on cardiac antibody-mediated rejection [1, 13].
The most recent paper has made some progress in deﬁning
the clinical entity and produced a tentative outline of a path-
ological diagnosis. The multidisciplinary and international
committeemadeimportantstepsforwardinagreeingonsev-
eral clinical aspects of cardiac humoral rejection. Cardiac
dysfunction, circulating antibodies, and donor-speciﬁc anti-
bodies are no longer required to make the diagnosis. In 2005,
cardiacdysfunctionwasconsideredtobeabsolutelyrequired.
Thus, the committee has acknowledged the possibility of
asymptomatic antibody-mediated rejection as published by
Wu et al. [14]andthattheantibodiesresponsiblemaysimply
not be detectable in the peripheral blood. However, a patho-
logic diagnosis is still required. While the committee did not
provide a grading scale at the moment, it did agree that the
pathologic diagnoses had to include evidence of endothelial
“activation” with evidence of intravascular macrophages,
neutrophil inﬁltration, and injury to the capillaries. The
committee felt that only capillary vessel analysis should be
included in the pathologic evaluation. Immunoﬂuorescence
should include evidence of complement activation by stain-
ing for C3d or C4d and staining for HLA to evaluate injury
to the endothelial capillaries. CD68 should be used to assess
for macrophage accumulation. In the case presented here,
we were unable to detect cellular or humoral rejection until
postmortem despite obtaining biopsies during her decline in
cardiac function. On her ﬁnal admission, biopsies were not
obtained because of her presentation with diarrhea and de-
hydrationandthelackofchangeinherechocardiogramfrom
one obtained four months earlier with a negative biopsy.
We may have been aided by the use of two potential
approaches. One approach was published in a recent study
by Kobashigawa et al. [15] which showed a correlation in
between low ATP levels (<200ng/mL) in peripheral blood
leukocytes and the incidence of infection in heart transplant
recipients using the ImmuKnow assay manufactured by
Cylex Inc. (Columbia, Md, USA). In this study, rejection and
infection episodes were analyzed in 337 patients who had
also undergone ImmuKnow assays. The patients were from
2 weeks to 10 years after-transplant and had undergone 1187
ImmuKnow assays. Assays from patients with an infection
or rejection event within one month prior to the assay were
not included (323 assays from 41 patients). All patients were
treated with a three-drug regimen (tacrolimus, mycophe-
nolate, and corticosteroids) without induction. Assay scores
were correlated with infection and rejection events that were
within one month after the ImmuKnow assay. While the
study is limited by its size, a signiﬁcant correlation wasfound
between a low assay score and an infection event occurring
withinonemonthofthemeasurement(187±126ngATP/mL
in 38 infections versus 280 ± 126ng ATP/mL in 18 patients
in steady state). The authors point out that the study was too
smalltodiscriminatebetweenpatientswithimpendingrejec-
tion and those in steady state. Intriguingly, the highest assay
scores were obtained in 3 of the 8 patients with rejection.
These patients had a score of 491 ± 121ng ATP/mL (signif-
icantly higher than those from patients in steady state) and
exhibited antibody-mediated rejection.
Another approach that may aid us in the future is the
possibility for the potential biopsy diagnosis of antibody-
mediated rejection involving the analysis of endothelial cellJournal of Transplantation 5
gene expression proﬁling [1, 16,17]. Speciﬁc gene expression
patterns may be indicative of endothelial injury and may
be detectable even without detecting complement products.
An approach utilizing the peripheral blood leukocyte assay
(ImmuKnow) and the gene expression proﬁle obtained at
biopsy may have helped us in earlier diagnosis of antibody-
mediatedrejectionandsteeredusawayfromfocusingprima-
rily on an infectious etiology.
3.4. Treating Humoral Rejection. Therapy in AMR should
aimtowardimproving graftdysfunction, prevention oflong-
term complications such as coronary allograft vasculopathy
(CAV), and improving graft survival. As mentioned above,
the International Society of Heart and Lung Transplantation
2005 guidelines included allograft dysfunction as required
criteriainthedeﬁnitionofAMR[13].Therecentrecommen-
dations suggesting that asymptomatic patients with AMR,
with no demonstrable graft dysfunction, have an increased
risk of coronary vasculopathy and death [1, 14] and that nei-
ther circulating nor donor-speciﬁc antibodies are required
for the diagnosis raise immediate practical therapeutic con-
cerns. First, the clinical impact of currently available therapy
for the asymptomatic patients without graft dysfunction
wouldbehardtomeasureandthusdemonstratingandmon-
itoring the beneﬁts would be diﬃcult in the short term. Also,
therapies directed at reducing circulating and donor-speciﬁc
antibodies would be impossible to evaluate in patients with
no detectable antibodies other than with repeat biopsies.
Again, the sampling bias of the biopsy would potentially lead
to false conclusions about eﬃcacy of treatment. Further risk
stratiﬁcation of these patients based on other parameters is
required. Nonetheless, the current recommendations revolve
around minimizing antibody-mediated myocardial injury.
The general therapeutic options include removing circulat-
ing antibodies, reducing activation and diﬀerentiation of B
lymphocytes, minimizing the activation of complement, and
suppression of T-cell activation [1].
Plasmapheresis is very eﬀective at rapid removal of circu-
lating antibodies. Two most frequently used techniques are
plasma exchange method and double-ﬁltration plasmapher-
esis [1]. Both forms of plasmapheresis are nonselective and
do not speciﬁcally remove immunoglobulins. Immunoad-
sorption plasmapheresis is a more speciﬁc modality of anti-
bodyremovalusinganadsorbentmembranebuttheexpense
and availability of the adsorbing membrane limits its utility
[1]. The duration of treatment can vary from days to weeks.
Ar e b o u n de ﬀect producing an increase in circulating an-
tibodies following plasmapheresis treatment requires ad-
ditional therapy either with intravenous immunoglobulin
(IVIG), calcineurin inhibitors (CNI), or rituximab (an anti-
CD20 monoclonal antibody targeting developing and ma-
ture B cells but not plasma cells). All three types of plasma-
pheresis carry the risk of volume depletion, infection, expo-
sure to fresh frozen plasma or the adsorption membrane [1].
Intravenous Immunoglobulin (IVIG) has been generally
used to treat allosensitization in patients with elevated panel
reactive antibodies prior to undergoing cardiac transplant
[18]. Successful IVIG therapy in treating renal and heart
transplantAMRhasbeenreported[19–21].Inonestudy,ﬁve
patients who met criteria for AMR (C4d, C3d deposition on
biopsy and with concomitant graft dysfunction) were treated
successfully with IVIG and plasmapheresis and two patients
with donor speciﬁc antibodies were given rituximab in com-
bination with plasmapheresis [22].
The eﬃcacy of antithymocyte globulin (ATG) in treating
AMR in heart transplantation is unclear, even though it has
beenusedtotreatAMRinrenaltransplantation[23].Calcin-
eurin inhibitors and antiproliferative agents such as myco-
phenolatemofetil(MMF)andsirolimus,whicharethemain-
stay immunosuppressive therapy in heart transplant, have
not beendirectlystudiedin treatingAMRin cardiacallograft
recipients. Tacrolimus therapy in combination with siroli-
mus or MMF may be superior in treating both cellular and
humoral rejection compared to cyclosporine/MMF-based
therapy [24].
Rituximab, which is known to inhibit activation and
maturation of B cells, has been used to treat AMR in heart
transplant patients. Rituximab, given as a weekly dose for up
to four doses and administered in combination with plasma-
pheresis, IVIG, and steroids, has been used successfully to
treat AMR and to reduce PRA in pre-heart transplant [25–
27]. The utility of bortezomib, a proteosome inhibitor used
fortreating multiple myeloma, whileused in renaltransplant
patients with AMR, is limited to desensitization protocols
for reducing panel reactive antibodies (PRA) in patients with
AMR, when used in combination with IVIG, rituximab, and
plasmapheresis [28, 29].
Complement activation is an important factor by which
circulatingalloantibodiesinducegraftinjury.Eculizamabisa
humanized monoclonal antibody which prevents activation
of complement component by binding to C5 and thus pre-
venting generation of C5a and the membrane attack com-
plex. Eculizamab has been approved for treatment of parox-
ysmal nocturnal hemoglobinuria in the USA. Early experi-
ence has shown success in treating AMR in renal transplant
patients [30, 31].
Total lymphoid irradiation has been used to treat rejec-
tion in heart transplant patients but appears to increase the
risk of hematologic malignancies [32]. Photopheresis has
been demonstrated by some to be successful in treating re-
current rejection in cardiac transplant recipients with severe
hemodynamicallycompromisingcellularrejection.Thismo-
dality appears to be better tolerated with fewer side eﬀects
[33]. Its utility in treating AMR in heart transplant has not
been established.
Notreatmentstrategyincardiactransplantationhascon-
sistently proven to be successful in treating AMR. Tacroli-
mus-based therapy, in combination with MMF and steroids,
appears to be eﬀective in preventing AMR. Future trials may
provide more insight into the utility of newer therapies with
rituximab, bortezomib, and anticomplement antibodies.
4. Summary
In its simplest formulation, the clinical eﬀorts of post-heart
transplant management involve three basic goals: prevent
rejection, minimize infection, and minimize the adverse side6 Journal of Transplantation
eﬀects of the immunosuppressive therapy. Currently, diag-
nosis is highly dependent upon pathological tissue evidence.
While patients can be treated empirically, the hope is that
advances in molecular biology including transcriptome and
proteomic analyses will help improve our ability to manage
patients following heart transplantation. New diagnostic
modalities will include reﬁnement of molecular testing to
provide diagnostic and prognostic markers for rejection
and infection. Newer treatment modalities for antibody-me-
diated rejection will target antibody production and com-
plement activation. It is likely that a percentage of patients
with unclear etiology of graft dysfunction may be suﬀering
from undiagnosed cellular and/or humoral rejection because
of the heterogeneous nature of the rejection process.
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